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ABSTRACT
Objective: Alzheimer disease (AD) is the most common cause of dementia, a syndrome characterized by cognitive impairment severe enough to interfere with activities of daily life. We aimed to conduct a systematic literature review (SLR) of studies that applied machine learning (ML) methods to clinical data derived from electronic
health records in order to model risk for progression of AD dementia.
Materials and Methods: We searched for articles published between January 1, 2010, and May 31, 2020, in
PubMed, Scopus, ScienceDirect, IEEE Explore Digital Library, Association for Computing Machinery Digital Library, and arXiv. We used predefined criteria to select relevant articles and summarized them according to key
components of ML analysis such as data characteristics, computational algorithms, and research focus.
Results: There has been a considerable rise over the past 5 years in the number of research papers using MLbased analysis for AD dementia modeling. We reviewed 64 relevant articles in our SLR. The results suggest that
majority of existing research has focused on predicting progression of AD dementia using publicly available
datasets containing both neuroimaging and clinical data (neurobehavioral status exam scores, patient demographics, neuroimaging data, and laboratory test values).
Discussion: Identifying individuals at risk for progression of AD dementia could potentially help to personalize
disease management to plan future care. Clinical data consisting of both structured data tables and clinical
notes can be effectively used in ML-based approaches to model risk for AD dementia progression. Data sharing
and reproducibility of results can enhance the impact, adaptation, and generalizability of this research.
Key words: Alzheimer disease, dementia, electronic health records, clinical data, machine learning

INTRODUCTION
Alzheimer disease (AD) is the most common cause of dementia,
which is a syndrome characterized by impairment of memory and/or
thinking severe enough to interfere with activities of daily life.1,2 AD
dementia affects millions of people worldwide and is currently the
sixth leading cause of death in the United States.3,4 AD-related brain

pathology, which includes the accumulation and deposition of amyloid-b peptide and tau protein, begins almost 10–20 years before the
onset of dementia symptoms.5 Therefore, many individuals with
early AD brain pathology are cognitively normal but at higher risk
for developing dementia in the future.6 AD dementia is progressive
and incurable, and, at advanced stages, patients suffer potentially
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fatal complications such as dehydration, malnutrition, or infection.7
Identifying individuals with early AD brain pathological changes
could lead to therapeutic interventions to delay the disease progression over time and could be helpful for tailoring disease management and planning future care.
Clinical data are defined as “information ranging from determinants of health and measures of health and health status to documentation of care delivery . . . captured for a variety of purposes and
stored in numerous databases across the healthcare system.”8 Nonimaging clinical data extracted from EHRs are some of the most accessible and widely used clinical datasets. They are an integral part
of contemporary healthcare delivery, enabling quick access to accurate, up-to-date, and complete patient information, and assisting in
accurate diagnosis and coordinated, efficient care.9 EHR data collected from individuals at risk for AD dementia can include laboratory test results, vital signs, medications, and other treatments
administered, as well as comorbidities.9,10 In some cases, patients
may also undergo specific testing for markers linked to AD brain pathology using expensive and/or invasive procedures such as neuroimaging scans (magnetic resonance imaging [MRI] and position
emission tomography [PET]) and cerebrospinal fluid (CSF) collection for biomarker testing.11–15 The results of these tests may also be
present in the EHR. Research has shown that such longitudinal clinical EHR data (ie, data collected from multiple time points) can be
utilized for monitoring the time-course of AD dementia progression.16
The widespread use and availability of medical devices over the
years have provided an overwhelming volume of clinical EHR data,
which could potentially augment the traditional tools of dementia
experts.17 The unmet needs for dementia expertise, coupled with the
relevant massive datasets, have encouraged researchers to examine
the utility of artificial intelligence (AI), which is gaining high visibility in the realm of healthcare innovation.18 Machine learning (ML),
a branch of AI, can model the relationship between the input quantities and clinical outcomes, discover hidden patterns within largescale data, and make inferences or decisions that help in more accurate clinical decision-making.19 However, computational hypotheses
generated by ML models still need to be validated by subject matter
experts in order to ensure adequate precision for clinical decisionmaking purposes.20 In our review, we include studies using ML for
the purpose of predictive modeling (such as decision trees, support
vector machines [SVM], k-means clustering) and exclude studies using statistical methods for cohort summarization and hypothesis
testing (such as odds ratio, Chi-square distribution, Kruskal–Wallis

test, Kappa-Cohen test). For studies using linear and logistic regression only those studies were included which utilized these methods
for predictive modeling or classification analysis.
The current literature generally neglects secondary use of nonimaging clinical data, including routinely collected EHR-derived
data, as a rich, low-cost, and noninvasive source of information for
identifying potential risk factors for AD dementia, and instead focuses on the use of costlier and/or invasive imaging and diagnostic
testing data for ML-based analysis. However, we believe that further
study of EHR-derived data could lead to more efficient, costeffective, timely, and personalized disease management for individuals with AD. With this motivation and a goal of identifying the
knowledge gaps and potential opportunities for the use of EHRderived data in conjunction with ML frameworks, our goal was to
conduct a systematic literature review (SLR) on the state-of-the-art
of ML as applied EHR-derived data for the purposes of modeling
and understanding AD dementia progression.

METHODS
As noted above, the motivation behind conducting an SLR is to summarize existing findings related to a chosen research topic to identify
gaps in literature and thus create a ground for future research work.
As stated by Martı-Juan et al,19 “Performing an SLR comprises the
following steps: (1) identify the need for performing the SLR; (2)
formulate research questions; (3) execute a comprehensive search
and selection of primary studies; (4) assess the quality and extract
data from the studies; (5) interpret the results; and (6) report the
SLR.” In this SLR, our main research question is: How are machine
learning algorithms being applied by researchers for studying progression of AD dementia using clinical EHR data? This main question can be subdivided further into the following 3 research
questions:
1. What type of ML methods have been used for detecting the onset of AD dementia and for predicting the trajectory of the disease progression?
2. What EHR-derived data types and risk factors (eg, physiological, genetics, demographics) have been used as features for predictive modeling?
3. What are the research foci of the reviewed articles that use ML
methods on EHR-derived data for modeling and predicting the
progression of AD dementia?
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LAY SUMMARY
Alzheimer disease (AD) is the most common cause of dementia, which is a syndrome of impaired memory and/or thinking
that interferes with activities of daily life. Many studies of AD dementia utilize information from expensive and invasive procedures, such as brain imaging or spinal taps, to estimate risk for developing AD dementia or rapid cognitive decline. However, widely available electronic health records (EHRs) systems contain a wealth of healthcare data describing a patient’s
medical history and clinical presentation (eg, demographics, vital signs, medications, laboratory data, current medical conditions) that could be leveraged as a low-cost, noninvasive alternative to study the progression of AD dementia. In recent
years, machine learning (ML) has become a useful tool in identifying hidden patterns within large-scale healthcare data,
such as the aforementioned EHR-derived data types, leading to increased efficiency and improved healthcare. We aim to
perform a systematic literature review of studies applying ML to clinical and EHR data to identify factors that predict risk for
progression of AD dementia. We summarize the reviewed articles according to key components of ML analysis such as data
characteristics, computational algorithms, and research focus. Finally, we identify gaps in the literature and potential opportunities for future research.
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Search strategy

For each of the 3 keyword groups, we selected the words as per standard terminologies used for manuscript notation in the targeted literature databases.19,21 The disease group consisted of different
words related to AD and dementia. We observed that the terms
“Mild Cognitive Impairment” and “MCI” often relate to brain diseases other than AD, so we excluded those to avoid false positives.
For the ML methodology group, we focused on all possible variants
related to ML/AI as well as general terms like prediction, classification, etc. The third group related to data and features consisted of
keywords related to clinical EHR data. Since the focus of the review
was on the use of clinical EHR-derived data with/or without imaging features, keywords related to imaging like “neuroimaging,”
“MRI,” “PET,” “CT,” etc., were not part of any inclusion or exclusion criteria.
For our SLR, we searched the following bibliographic databases:
(1) PubMed; (2) Association for Computing Machinery Digital Library; (3) IEEE Explore Digital Library; (4) ScienceDirect; (5) Scopus; and (6) arXiv/BioarXiv. Works originally identified from
arXiv/BioarXiv were subsequently verified to have been accepted in
a peer-reviewed journal or conference. Using each search engine, we
searched the titles, abstracts, and keyword sections of articles published in journals or conference proceedings between January 1,
2010, and May 31, 2020. In order to limit our search to the scope of
the review, our search string in each of the online databases was a
triplet with 1 keyword from each of the 3 groups. All possible string
combinations were created by taking 1 term from each of the 3 keyword groups joined by an “AND.” The set of above formed triplets
were then used as queries for the search.

Exclusion criteria
The entire procedure of article searching and inclusion/exclusion criteria was performed according to the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guidelines.22 The
inclusion/exclusion criteria were reviewed by a board-certified neurologist and dementia specialist. All articles were selected and
screened for eligibility by a doctoral student. In the first phase of
screening, all duplicate articles collected from the different source libraries were removed. The next phase of screening discarded all
papers that were clearly not relevant to the review, including studies
where the abstract and the title did not contain any of the keywords
related to “Alzheimer disease” or “Machine Learning.” Following
the approach adopted by the authors in ref,21 the articles that
passed the screening phase were assessed for eligibility by reviewing

the full texts of the remaining articles to exclude studies which met
one or more of the exclusion criteria (Table 1).

Study risk of bias assessment
To mitigate the risk of bias during the search process and inclusion/
exclusion of the articles, a series of checks were implemented during
the article selection process. All articles were selected and screened
for eligibility by a doctoral student. Two additional authors validated the final set of papers and review analysis. The final selected
articles and inclusion/exclusion criteria were also reviewed by a
board-certified neurologist and dementia specialist for relevance to
our main research question.

Summary statistics
Replicating the method followed in ref, 21 we calculated the following summary statistics from the final set of included articles: (1)
source and publication year of article; (2) research focus of the article; (3) modality and accessibility of dataset; (4) size of cohort and
type of features/risk factors; and (5) type of ML model for predictive
modeling.

RESULTS
Figure 1 shows the PRISMA flowchart, which depicts the selection
process by which we arrived at the final set of included studies. We
identified a total of 1331 studies from the different bibliographic
databases. Since many papers were included in multiple databases,
the first exclusion step removed 405 duplicate articles. From the
remaining 926 articles, we removed 345 studies that were out of the
scope of our review. This includes articles where the title or abstract
did not contain any of the keywords related to “Alzheimer disease”
or “Machine Learning.” We reviewed 581 full-text articles for eligibility based on the exclusion criteria described in Table 1. After filtering on one or more of the exclusion criteria in Table 1, 64 articles
remained for review.
Figure 2 shows the distribution of the reviewed articles by their
publication year. The value shown for the year 2020 only includes
data until May, when we performed the search. As shown by the
plot, the count of published papers relevant to our scope has increased over the past 5 years, demonstrating that interest in using
ML for analyzing AD with clinical data is on an upward trajectory.

Data characteristics
To understand the nature of the data used by researchers in their
articles, we documented the accessibility of the dataset, the number
of included human subjects, and the incorporated clinical features.
For each of the articles, we checked if the authors provided directions on how to access the dataset used in their experiments. We observed 2 main categories of datasets from our analysis: (1)
deidentified datasets that are publicly available for download and
(2) restricted datasets from sources like institutional clinical datasets
that are not available for public use.
For the first category, we found that the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) dataset was the most widely used,
with 64% (41/64) of articles using ADNI for longitudinal AD data.
ADNI enrolls participants between the ages of 55 and 90 at sites in
the United States and Canada. After obtaining informed consent,
participants undergo a series of neuropsychological and clinical
assessments, genetic testing, and imaging (MRI and PET) at multiple
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The aim of this SLR is to review works that meet the following criteria: (1) focus on modeling and predicting the onset or progression of
AD dementia; (2) use ML techniques; and (3) use clinical markers of
patients diagnosed with AD dementia. Similar to ref, 19 we created
3 keyword groups as follows, each relevant to different aspects of
the scope of the review.
1. Keywords related to disease: AD, Alzheimer’s, Alzheimer, Alzheimer’s disease, dementia, Alzheimer’s Disease, and Related
Dementia.
2. Keywords related to ML methodology: ML, machine learning,
AI, artificial intelligence, pattern recognition, computer-aideddiagnosis, CAD, classification, prediction, supervised learning,
unsupervised learning, predictive modeling.
3. Keywords related to data and features: electronic health records,
EHR, clinical data, clinical assessments, patient health data.
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Table 1. Exclusion criteria for research articles

1.
2.

5.
6.

7.

Reasons for exclusion

Only neuroimaging features were considered for predictive
modeling
ML methods were not used for clinical predictive modeling
related to AD/dementia

Scope of the review was inclusion of clinical EHR-derived
data with/or without imaging features
We excluded articles which performed cohort summarization and hypothesis testing using statistical methods like
logistic regression odds ratio, Chi-square distribution,
Kruskal–Wallis test, etc.
AD/dementia is not the focus of the main analyses
AD/dementia is not the focus of the main analyses

Focus on a disease other than AD/dementia
AD/dementia is used only as an example of a neurodegenerative disease
Not peer-reviewed conference proceedings, journal, or preprints
Multiple publications from the same research group with
similar final outcomes. In such cases, only the most recent
studies were considered
Review articles

Outside the scope of our review
Considered to be duplicate articles

Review articles did not focus on a specific research goal

Abbreviations: AD: Alzheimer disease; EHR: electronic health record; ML: machine learning.

Figure 1. PRISMA flow diagram. Abbreviation: ACM: Association for Computing Machinery.

timepoints over subsequent years.23 Other data sources included the
National Alzheimer’s Coordinating Center;24–26 Australian Imaging,
Biomarker & Lifestyle Flagship Study of Ageing;27 Framingham
Heart Study;28,29 and Coalition Against Major Databases.30 These
datasets are all publicly available for download with some requiring
a license from their respective websites.

For the second category, 16 out of 64 papers used their own customized clinical datasets. We deemed such datasets “restricted data”
when there were no references or external links through which the
data could be accessed. Examples of restricted datasets analyzed in
these papers included a dataset subsampled from the National
Health Insurance Service—national sample cohort of 1 million
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people representative of the South Korean population within the Korean National Health Insurance Service database31 and a dataset
collected from people who received a screening test in the dementia
center in Gangbuk-Gu, Seoul, from 2008 to 2013.32
The performance of an ML framework depends significantly on
the size of the training cohort. From each of the reviewed articles,
we determined the number of patients whose health data were used
for analysis of AD dementia. Based upon the observed cohort sizes
in all the included studies, we divided the cohort sizes into 4 categories: (1) 0–1000 patients; (2) 1001–10 000; (3) 10 001–100 000; and
(4) >100 000. Figure 3 shows the number of studies corresponding
to each cohort size category. Three articles33–35 did not report the
cohort sizes; so, we excluded them from our analysis of Figure 3.
Most of the studies had cohort sizes of 0–1000 patients (n ¼ 34), followed by 1001–10 000 patients (n ¼ 15), 10 001–100 000 patients
(n ¼ 5), and finally >100 000 patients (n ¼ 7).

AD dementia features and biomarkers
Data of patients analyzed for risk of AD dementia consist of clinical
variables like laboratory results, vital signs, neurobehavioral status
exam scores, demographic information, and comorbidities, along
with neuroimaging scans and CSF biomarkers. ML models try to
learn the relationships amongst a set of clinical variables and determine if and how these variables contribute to the model predicting
the development of AD dementia. Although the scope of this review

Figure 3. Size of cohort used in the reviewed studies.

focused on articles using nonimaging clinical data, some of these
studies used multimodal datasets with nonimaging clinical and imaging features. To determine the prevalence of the use of nonimaging clinical features as potential AD risk factors, we classified the
included studies into the following 2 categories: (1) Clinical only—
only nonimaging clinical variables36,37and (2) Clinical þ Imaging—
imaging and nonimaging clinical variables were integrated to form
the complete set of features.38–41 We grouped the features into the
following categories: neuroimaging features,35,42,43 cognitive assessments,44–47 genetic factors,48–51 laboratory test values,52–54 patient
demographics,55–57 and clinical notes.
Table 2 summarizes the feature categories and measures/factors
used while applying the ML framework along with the count of
articles using that particular variable. In our cohort of studies that
used data from neuroimaging techniques as features for predictive
modeling, MRI was the most widely used.35,42,43 As shown in Table
2, cognitive assessments (48 studies) and demographics (47 studies)
were the 2 most common features used by researchers for analysis of
AD dementia. Only 4 articles considered clinical notes, primarily patient medical history and diagnosis details documented by clinicians.58–61 Thirty studies (47%) were categorized as Clinical only
and 34 (53%) as Clinical þ Imaging. Figure 4 shows the relationship
between the nature of data access restrictions (publicly available or
restricted) and the category of AD dementia features (Clinical only
or Clinical þ Imaging). As illustrated by the figure, 94% (32/34) of
the Clinical þ Imaging data were extracted from publicly available
datasets. For the Clinical only studies, 57% (17/30) of the Clinical
data originated from datasets which are not publicly accessible.

Application of ML methods
ML tools can model complex relationships between different clinical
variables that are often beyond human capabilities. The output of
trained ML models when applied on previously unseen healthcare
clinical data yield inferences that can augment clinical decision-making. With the advancement of computational resources, researchers
have progressed from simple ML algorithms like regression to complex deep learning models. We examined the different categories of
ML techniques used in the reviewed articles based on the model type
and the type of learning algorithm. We grouped the ML methods
based on model type into the following categories: regression,52,62,63
SVM,64–66 decision tree,67–69 Bayesian networks,70–72 neural networks,33,73,74 and natural language processing (NLP). The neural
networks category includes both classifiers such as multilayer perceptron and deep learning models such as convolutional neural networks and autoencoders.75–77 Based on the type of learning
algorithm, ML models can either be supervised, unsupervised, or
semi-supervised. In a supervised learning model, the algorithm is
trained on a dataset annotated with gold standard labels. Unsupervised learning models, on the other hand extract features and patterns from unlabeled data and cluster the data points into distinct
classes. Semi-supervised learning is a hybrid of the above 2 methods
and combines a small amount of labeled data with a large volume of
unlabeled data during training. Regression, SVM, decision trees,
Bayesian networks, and neural networks all fall under the supervised
category. k-Means algorithm is an example of unsupervised learning.60
Table 3 summarizes the types of ML models based on model
type along with their different variants. The most widely used techniques were decision trees (50%), neural networks (44%), regression (34%), SVM (34%), and Bayesian networks (20%). NLP was
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Figure 2. Studies published per year which use machine learning on clinical
data for prognostic estimates of Alzheimer’s Disease. For 2020, studies dated
till May 31st were considered for the review.
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Table 2. Features related to AD dementia identified by articles
Measures/factors

Number of articles (%)

Neuroimaging
Cognitive assessments
Genetic
Laboratory
Demographics
Clinical notes

MRI (structural, functional, unspecified), PET (FDG, amyloid)
MMSE, ADAS-Cog, others (CDR, FAQ)
APOE e4, family history
CSF, vitals, medications, medical history, other laboratory tests
Age, gender, education, race
Discharge summary

35 (54%)
48 (75%)
24 (38%)
32 (50%)
47 (72%)
4 (6%)

Abbreviations: AD: Alzheimer disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE e4: apolipoprotein epsilon 4 allele; CDR:
clinical dementia rating; CSF: cerebrospinal fluid; FAQ: Functional Activities Questionnaire; FDG, ; MMSE: Mini-Mental State Exam; MRI: magnetic resonance imaging; PET: position emission tomography.

ples.86 For our review, we analyzed if the authors have provided adequate details about the dataset used and the implementation to
check if the FAIR principles were followed. Only 7 (11%) of the
articles reported their implementation code27,37 and 48 (75%) studies used publicly available datasets.36,38,41

DISCUSSION

Figure 4. Relationship between the modality and accessibility of the datasets
used in the included studies.

used only in studies which included patient clinical notes as one of
the features; these comprised 6% of all studies.58–61

Research foci of the reviewed articles
Identifying the research foci or the end goals of the reviewed articles
can provide insights into how applying ML techniques on clinical
EHR data can lead to effective clinical decision-making. More than
half of the reviewed articles (55%, 35/64) investigated the progression of AD dementia to determine if an individual had stable or progressive AD. They aimed to predict the development of AD
dementia in individuals who were initially cognitively normal or had
only mild cognitive impairment.34,78,79 Eleven/sixty-four (17%)
studies used data comprised of longitudinal trajectories of clinical
variables from patients showing mild symptoms of dementia to train
predictive models for personalized forecasting of disease progression.80–82 Eighteen/sixty-four (28%) studies in our review aimed to
satisfy both the above objectives. For example,83,84 presented a computational ML-based framework for modeling symptom trajectories
using cognitive assessment scores at multiple time points and subsequently predicting those trajectory classes using multimodal data
comprising both clinical and imaging variables.

Reproducibility
Reproducibility, a fundamental requirement of the scientific process,
is related to the idea that a scientific experiment should be able to be
reproduced to validate its results.85 The reproducibility of a scientific study is often assessed by the extent to which it follows the
FAIR (Findable, Accessible, Interoperable and Reusable) princi-

AD is the most common cause of dementia, which is a syndrome of
impaired memory and/or thinking that interferes with activities of
daily life. We performed an SLR of studies applying ML to clinical
data to identify factors that predict risk for progression of AD dementia. There has been an exponential increase in such paper applying ML for AD over the past 3 years. We reviewed the selected
articles according to key components of ML analysis such as data
characteristics, computational algorithms, and research focus; in the
process we identified gaps in the existing literature and potential opportunities for future research. Our review suggests that most of the
articles focus on predicting the progression of the disease based on
standardized publicly available multimodal datasets which include
both neuroimaging and some nonimaging clinical data. Most commonly used nonimaging clinical features for predictive modeling include neurobehavioral status exam scores, patient demographics,
neuroimaging data, and laboratory test values.
Clinical databases which are collected for specific research purposes (eg, data in clinical registries) or cleaned and curated to enhance
data reusability (eg, MIMIC database87) are often relatively wellstructured, standardized, and clean, even though they may still have a
few missing values and outliers. Hence, many researchers focus on utilizing these relatively clean datasets for their experiments and methodological innovations. However, as we noted previously, clinical data
from local sources like institutional EHRs, which are primarily used to
track patient care but can also be used secondarily for clinical research
and automated disease surveillance, have great potential for use in
modeling AD dementia progression.88 Data from such raw EHR data
sources often have data quality issues and require significant effort for
data preprocessing and feature engineering. However, they are a rich
source of historical clinical data containing patient-level elements
which can be effectively leveraged using ML-based computational
techniques for longitudinal analyses of their preclinical phase to identify prognostic clinical phenotypes, thus representing an opportunity
to employ precision medicine paradigms in disease states where the
current evidence-base precludes such an approach.
The basic criteria for selecting articles for our review was inclusion of clinical data excluding imaging with/or without other features
and/or data types. We observed that a significant portion of articles
employed neuroimaging features from structural and functional MRI
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Table 3: Specific computational and machine learning methods utilized
Specific models

Regression

Linear regression
Logistic regression
Lasso regression
Ridge regression
Support vector regression
SVM with linear kernel
SVM with RBF kernel
SVM with polynomial kernel
Support vector regression
Decision trees
Random forest
Adaboost
GBM
Naı̈ve Bayes model
Bayesian belief networks
GMM
Multilayer perceptron
CNN-based models
RNN-based models
Autoencoder
RBM
Graph neural networks
Text mining
KNN
k-Means

SVM

Decision trees

Bayesian networks

Neural networks

NLP
Others

Number of articles (%)
22 (34%)

22 (34%)

32 (50%)

13 (20%)

28 (44%)

4 (6%)
7 (11%)

Abbreviations: CNN: convolutional neural network; GBM: gradient boosting models; GMM: Gaussian mixture model; KNN: K-nearest neighbor; NLP: natural language processing; RBF: radial basis function; RBM: restricted Boltzmann machines; RNN: recurrent neural network; SVM: support vector machines.

as well as fluorodeoxyglucose (FDG) and amyloid positron emission
tomography (PET) for predictive modeling; this indicates that most
researchers use clinical features as part of multidimensional datasets
containing both clinical and imaging features. As evident from the relationship between the modality and accessibility of the datasets,
multimodal features are mostly derived from the category of publicly
accessible, standardized, and well-curated datasets.
Identifying individuals with early AD brain pathological changes
could enable therapeutic interventions to delay the disease progression over time and can be helpful for tailoring disease management
and planning future care. Multiple failed drug trials for AD dementia show that in the later stages of the disease course, when the patient already has significant neuronal degeneration, treatment is
unlikely to be helpful.89 Hence, many drug trials are now enrolling
patients with either preclinical AD (cognitively normal individuals
with AD-related brain pathology) or very early AD dementia.90,91
Most studies reported that their proposed methodology can identify
individuals at risk for progression to AD dementia approximately
24–48 months before the diagnosis of AD dementia.
Nearly all of the reviewed articles used supervised learning in the
proposed models. Unsupervised or semi-supervised learning can also
be an effective tool for handling multidimensional longitudinal patient data where clinical outcomes are not known a priori. Unsupervised clustering algorithms can be helpful for identifying novel
subphenotypes with distinct disease trajectories and the associations
between them.89,92
EHR-derived data for patients who are screened for risk of AD
dementia not only include structured data in the form of labs, medications, and procedures, but also clinical notes, which are textual
descriptions of physician–patient encounters and records of their
follow-up visits.93 We observed from the summary statistics that in-

formation from clinical notes are not often included for developing
the predictive modeling pipelines. However, these notes often consist of additional clinical information that are usually unavailable in
the structured data sources, offering a rich source of information for
clinical decision-making. Most of the notes are free-text narratives
lacking a standardized structure and they cannot be processed by
conventional ML algorithms like SVM, decision trees, regression,
etc. NLP is a field of computational techniques that offers a viable
solution for effectively processing clinical notes. In recent years,
deep learning-based NLP models like recurrent neural networks and
long short-term memory networks have been shown to outperform
the conventional word-embedding-based NLP techniques for
extracting relevant information from clinical notes.94
Data sharing and reproducibility of results can also enhance the
impact, adaptation, and generalizability of research. Ideally, measures
such as use of standardized publicly available EHR-derived datasets
and specification of implementation details can help ensure reproducibility of the published methods and results. However, siloed data between different academic and corporate institutions and inconsistent
data formats often make data sharing difficult and therefore remains
an open area of research and innovation.95 A solution to this problem
is developing a culture of data sharing among different institutions,
potentially utilizing common data models like the OHDSI (Observational Health Data Sciences and Informatics) data sharing initiative.
OHDSI produces tools like the OMOP (Observational Medical Outcomes Partnership) Common Data Model, which transforms data
within disparate observational databases into a common representation (terminologies, vocabularies, and coding schemes) so that they
can be analyzed using standardized analytics tools.96
Despite these limitations, there have been significant advancements in the application of ML on EHR-derived data for predicting
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Limitations of SLR
Many relevant research works might be published in only conferences and workshops proceedings and not indexed in bibliographic
databases. Similarly, some studies from arXiv/BioarXiv were not included since they were not yet peer-reviewed. Thus, identification of
only peer-reviewed studies from bibliographic databases might lead
to selection bias during the initial inclusion stage. This can potentially impact the results presented as it may not truly represent the
growing interest in the domain of using ML models for AD prediction using clinical data.

CONCLUSION
We performed an SLR of studies using ML on clinical EHR data for
modeling and prediction of AD dementia progression. We summarized different aspects of the articles including data source and modality, features, methods, and research focus of the studies. The
summarized results suggest that most state-of-the-art research on
AD has focused on predicting the progression of the disease based
on standardized publicly available multimodal datasets which include both neuroimaging and some nonimaging clinical data. The
nonimaging clinical data used most commonly for predictive modeling include neurobehavioral status exam scores, patient demographics, neuroimaging data, and laboratory test values. Almost all
the reviewed articles utilized supervised learning with common ML
models such as neural networks, decision trees, SVM, and regression. ML and other analytic approaches in AI can generate helpful
insights about complex clinical patterns that assists clinicians in
their decision-making and leads to improved quality, safety, and
outcomes of healthcare planning.
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